oss) per Share of Common Stock:Income from Continuing Operations$
2.13$
.46Loss from Discontinued Operations, Net of Tax$
(0.03)$
(0.09)Net Income$
2.10$
.37Diluted Earnings/(Loss) per Share of Common Stock:Income from Continuing Operations$
2.09$
.46Loss from Discontinued Operations, Net of Tax$
(0.03)$
(0.09)Net Income$
2.06$
.37Weighted Average Shares OutstandingBasic29,70329,468Diluted30,31429,564CAMBREX CORPORATIONConsolidated Balance SheetsAs of December 31, 2012 and 2011(in thousands)December 31,December 31,Assets20122011Cash and Cash Equivalents
$
23,551$
31,921Trade Receivables, net43,09436,510Inventories, net71,22162,095Prepaid Expenses and Other Current Assets6,1046,083 Total Current Assets143,970136,609Property, Plant and Equipment, net151,815139,628Goodwill37,31236,731Intangible Assets, net4,0914,261Investments in and Advances to Partially-Owned Affiliates15,09415,090Deferred Income Taxes39,2627,087Other Non-Current Assets2,9243,425 Total Assets
$
394,468$
342,831Liabilities and Stockholders' EquityAccounts Payable
$
27,612$
21,200Deferred Revenue11,5701,060Accrued Expenses and Other Current Liabilities43,84436,873 Total Current Liabilities83,02659,133Long-Term Debt64,00098,000Deferred Income Taxes18,57723,330Accrued Pension Benefits55,37352,089Other Non-Current Liabilities10,1959,938 Total Liabilities
$
231,171$
242,490 Stockholders' Equity
$
163,297$
100,341 Total Liabilities and Stockholders' Equity
$
394,468$
342,831CAMBREX CORPORATIONReconciliation of EBITDAFor the Quarters and Twelve Months Ended December 31, 2012 and 2011(in thousands)Fourth Quarter 2012Fourth Quarter 2011Operating Profit
$
7,417$
5,823Depreciation and Amortization5,6415,799EBITDA
$
13,058$
'/>"/>
SOURCE Cambrex Corporation Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine technology :1.
Cambrex Reports First Quarter 2012 Results2.
Cambrex To Present At Jefferies 2012 Global Healthcare Conference3.
Cambrex Announces Significant New Supply Agreement4.
Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 20125.
Cambrex Reports Third Quarter 2012 Financial Results6.
Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 20137.
Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events8.
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.9.
Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 201210.
Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 201211.
Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter